Domino liver transplantation in maple syrup urine disease

Liver Transplantation

Volumn 12, Issue 5, 2006, Pages 876-882

  Khanna, Ajai ^a   Hart, Marquis ^a   Nyhan, William L ^a   Hassanein, Tarek ^b   Panyard Davis, Janice ^a   Barshop, Bruce A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOISOLEUCINE; BRANCHED CHAIN AMINO ACID; CARBON DIOXIDE; CISPLATIN; DOXORUBICIN; LEUCINE; MITOMYCIN;

ADULT; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; CADAVER DONOR; CASE REPORT; FEMALE; HEPATITIS C; HUMAN; LAPAROSCOPIC SURGERY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MAPLE SYRUP URINE DISEASE; PRIORITY JOURNAL; PROTEIN DIET; RADIOFREQUENCY ABLATION; RECIPIENT; SURGICAL TECHNIQUE; SURVIVAL; SYMPTOM; TREATMENT OUTCOME;

ADULT; CARBON DIOXIDE; FEMALE; HUMANS; LEUCINE; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MAPLE SYRUP URINE DISEASE; MIDDLE AGED; OXIDATION-REDUCTION;

EID: 33646438536     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20744     Document Type: Article

References (34)

1. Chuang DT, Shih VE, Scriver CR. Maple syrup urine disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, vol 2. New York: McGraw-Hill, 2002:1971-2005.
2. Strauss KA, Morton DH. Branched-chain ketoacyl dehydrogenase deficiency: maple syrup disease. Curr Treat Options Neurol 2003;5:329-341.
3. Bellary S, Hassanein T, Van Thiel DH. Liver transplantation for Wilson's disease. J Hepatol 1995;23:373-381.
4. Blanchard H, Bensoussan AL, Weber A, Gauthier M, Lacroix J, Charest J, et al. Pediatric liver transplantation: the Montreal experience. J Pediatr Surg 1989;24:1009-1012.
5. Todo S, Starzl TE, Tzakis A, Benkov KJ, Kalousek F, Saheki T, et al. Orthotopic liver transplantation for urea cycle enzyme deficiency. Hepatology 1992;15:419-422.
6. Yorifuji T, Muroi J, Uematsu A, Nakahata T, Egawa H, Tanaka K. Living-related liver transplantation for neonatal-onset propionic acidemia. J Pediatr 2000;137:572-574.
7. van't Hoff WG, Dixon M, Taylor J, Mistry P, Rolles K, Rees L, Leonard JV. Combined liver-kidney transplantation in methylmalonic acidemia. J Pediatr 1998;132:1043-1044.
8. Chakrapani A, Sivakumar P, McKiernan PJ, Leonard JV. Metabolic stroke in methylmalonic acidemia five years after liver transplantation. J Pediatr 2002;140:261-263.
9. Nyhan WL, Gargus JJ, Boyle K, Selby R, Koch R. Progressive neurologic disability in methylmalonic acidemia despite transplantation of the liver. Eur J Pediatr 2002;161: 377-379.
10. Netter JC, Cossarizza G, Narcy C, Hubert P, Ogier H, Revillon Y, et al. Mid-term outcome of 2 cases with maple syrup urine disease: role of liver transplantation in the treatment. Arch Pediatr 1994;1:730-734.
11. Wendel U, Saudubray JM, Bodner A, Schadewaldt P. Liver transplantation in maple syrup urine disease. Eur J Pediatr 1999;158(Suppl 2):S60-S64.
12. Organ Procurement and Transplantation Network. http://www.optn.org/, 2004.
13. Mor E, Klintmalm GB, Gonwa TA, Solomon H, Holman MJ, Gibbs JF, et al. The use of marginal donors for liver transplantation. A retrospective study of 365 liver donors. Transplantation 1992;53:383-386.
14. Yacoub MH, Banner NR, Khaghani A, Fitzgerald M, Madden B, Tsang V, et al. Heart-lung transplantation for cystic fibrosis and subsequent domino heart transplantation. J Heart Transplant 1990;9:459-466; discussion 466-457.
15. Azoulay D, Samuel D, Castaing D, Adam R, Adams D, Said G, Bismuth H. Domino liver transplants for metabolic disorders: experience with familial amyloidotic polyneuropathy. J Am Coll Surg 1999;189:584-593.
16. Terazaki H, Ando Y, Nakamura M, et al. Variant transthyretin in blood circulation can transverse the blood-cerebrospinal barrier: qualitative analyses of transthyretin metabolism in sequential liver transplantation. Transplantation 2001;72:296-299.
17. Donckier V, El Nakadi I, Closset J, Ickx B, Louis H, Le Moine O, et al. Domino hepatic transplantation using the liver from a patient with primary hyperoxaluria. Transplantation 2001;71:1346-1348.
18. Popescu I, Simionescu M, Tulbure D, Sima A, Catana C, Niculescu L, et al. Homozygous familial hypercholesterolemia: specific indication for domino liver transplantation. Transplantation 2003;76:1345-1350.
19. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33: 464-470.
20. Elsas LJ, Ellerine NP, Klein PD. Practical methods to estimate whole body leucine oxidation in maple syrup urine disease. Pediatr Res 1993;33:445-451.
21. Bodner-Leidecker A, Wendel U, Saudubray JM, Schadewaldt P. Branched-chain L-amino acid metabolism in classical maple syrup urine disease after orthotopic liver transplantation. J Inherit Metab Dis 2000;23:805-818.
22. Schadewaldt P, Bodner-Leidecker A, Hammen HW, Wendel U. Whole-body L-leucine oxidation in patients with variant form of maple syrup urine disease. Pediatr Res 2001;49:627-635.
23. Hoerr RA, Yu YM, Wagner DA, Burke JF, Young VR. Recovery of 13C in breath from NaH13CO3 infused by gut and vein: effect of feeding. Am J Physiol 1989;257(Pt 1): E426-E438.
24. Hoffmann G, Aramaki S, Blum-Hoffmann E, Nyhan WL, Sweetman L. Quantitative analysis for organic acids in biological samples: batch isolation followed by gas chromatographic-mass spectrometric analysis. 1989:35:587.
25. Pacheco-Moreira LF, de Oliveira ME, Balbi E, et al. A new technical option for domino liver transplantation. Liver Transpl 2003;9:632-633.
26. Kaplan P, Mazur AM, Smith R, et al. Transplantation for maple syrup urine disease (MSUD) and methylmalonic acidopathy (MMA). J Inherit Metab Dis 1997;20(Suppl 1):37.
27. Merinero B, Perez-Cerda C, Sanz P, Font LM, Garcia MJ, Martinez Pardo M, et al. Liver transplantation (LT) in a Spanish MSUD patient. 32nd Annual Symposium, Society for the Study of Inborn Errors of Metabolism, 1994, Edinburgh. 64.
28. Suryawan A, Hawes JW, Harris RA, Shimomura Y, Jenkins AE, Hutson SM. A molecular model of human branched-chain amino acid metabolism. Am J Clin Nutr 1998;68:72-81.
29. Thompson GN, Bresson JL, Pacy PJ, Bonnefont JP, Walter JH, Leonard JV, et al. Protein and leucine metabolism in maple syrup urine disease. Am J Physiol 1990; 258(Pt 1):E654-E660.
30. Thompson GN, Walter JH, Leonard JV, Halliday D. In vivo enzyme activity in inborn errors of metabolism. Metabolism 1990;39:799-807.
31. Thompson GN, Francis DE, Halliday D. Acute illness in maple syrup urine disease: dynamics of protein metabolism and implications for management. J Pediatr 1991; 119(Pt 1):35-41.
32. Schadewaldt P, Wendel U. Metabolism of branched-chain amino acids in maple syrup urine disease. Eur J Pediatr 1997;156(Suppl 1):S62-S66.
33. Schadewaldt P, Bodner A, Brosicke H, Hammen HW, Wendel U. Assessment of whole body L-leucine oxidation by noninvasive L-[1-13C]leucine breath tests: a reappraisal in patients with maple syrup urine disease, obligate heterozygotes, and healthy subjects. Pediatr Res 1998;43: 592-600.
34. Luzi L, Regalia E, Pulvirenti A, Piceni Sereni L, Spessot M, Romito R, et al. Post-absorptive and insulin-mediated muscle protein metabolism in liver-transplanted patients. Acta Diabetol 2002;39:203-208.